Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
352 Elacestrant has emerged as the first FDA-approved oral estrogen receptor antagonist for ESR1 -mutant patients, owing to substantial improvements in progression-free survival (PFS) observed during the EMERALD phase 3 trial in the ESR1 -mutant population
Brennan BP, Rauch SL, Jensen JE, Pope HG Jr
Effects of the diuretics furosemide, ethacrynic acid, and chlorothiazide on gluconeogenesis from various substrates in rat kidney cortex slices
H tr tng sinh collagen: Vitamin C tham gia tng hp collagen, h tr da n hi, sn chc, gim np nhn
US$ 20.26
US$ 28.16
US$ 26.56
US$ 29.73
US$ 25.95
US$ 23.56
US$ 29.36
